12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial aims to study the efficacy and safety of 12 weeks adjuvant docetaxel plus
trastuzumab in patients with tumors ≤1cm, node-negative, HER2-positive breast cancer.